Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

IsnoonesafefromtheFTC?HasPfizerbottomedout?Andisbiotechfinallyback?Wecoverallthatandmorethisweekon“T AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha




Wikipedia

author：entertainment    Page View：49
A purple number 3 with an eye is surrounded by smaller, black number 3s on a green background — 3 to watch coverage from STAT
Christine Kao/STAT

Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather for the J.P. Morgan Healthcare Conference to pick apart the year that was and prognosticate about the one to come. The consensus, in good markets and bad, is almost always cautious optimism for boom times ahead, a prediction that in recent years has had groundhog-level accuracy.

But after two years of steady decline, 2024 might finally prove them right. Biotech is on the upswing, driven by the rise of some headline-grabbing medicines, the advance of cutting-edge technologies, and a few reminders that big drug companies are still willing to pay billions of dollars for small ones.

advertisement

Here are three major themes that we expect to drive the news in 2024 and determine whether biotech’s comeback is a sustainable trend or an interest-rate phenomenon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Heart disease and mental health: A look at cardiac psychology
Next article： The cancer drug shortage isn’t new — and neither are the solutions